Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

51.99 -0.97 (-1.84%)
Streaming Delayed Price Updated: 1:21 PM EDT, Aug 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2 3 4 5 6 7 8 9
...
45 46 Next >
News headline image
Gibson Energy (GEI) Q2 2026 Earnings Call Transcript ↗
Record infrastructure EBITDA and improved marketing guidance signal strong momentum. 
Via The Motley Fool
Topics Earnings
News headline image
GSK Q2 Earnings Call Highlights ↗
GSK (NYSE:GSK) reported second-quarter sales growth of 5% at constant exchange rates to more than £8.4 billion, supported by Specialty Medicines and Vaccines, while outlining a new cost-savings and... 
Via MarketBeat
Topics Earnings Intellectual Property
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AtaiBeckley Inc. (Nasdaq – ATAI), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)
From Brodsky & Smith LLC
Via GlobeNewswire
GSK PLC-SPON ADR (NYSE:GSK) Passes Quality-Focused Caviar Cruise Stock Screener with Strong Profitability and Cash Flow ↗
Via Chartmill
News headline image
Core Restore Founder Ann Peets Announces Bladder Leak Treatments In Charleston
Via Press Release Distribution Service
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
Via Investor Brand Network
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Arcosa, Inc. (NYSE – ACA), Fathom Holdings Inc. (Nasdaq – FTHM), Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
From BioMedWire
Via GlobeNewswire
News headline image
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
From GSK plc
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN), SUNation Energy, Inc. (Nasdaq – SUNE), Taylor Morrison Home Corporation (NYSE - TMHC)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
MarketBeat Week in Review – 06/08 - 06/12 ↗
Stocks rallied on optimism surrounding a potential U.S.-Iran peace deal and SpaceX's historic IPO debut, reinforcing investor confidence and market momentum 
Via MarketBeat
Topics Economy Initial Public Offering
News headline image
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion ↗
GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff. 
Via MarketBeat
Topics Intellectual Property
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq – NUVL), SUNation Energy, Inc. (Nasdaq – SUNE), Organon & Co. (NYSE – OGN), Taylor Morrison Home Corporation (NYSE – TMHC)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More ↗
Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Income Fund Just Completely Exited Its $37 Million Stake in Algonquin Power. Why? ↗
Algonquin serves approximately 1.3 million customer connections across the United States, Canada, Bermuda, and Chile through its regulated utility network. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults
From GSK plc
Via Business Wire
News headline image
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat ↗
Via MarketBeat
News headline image
Mondrian Dumps 5.5 Million Yum China Shares Worth $284.6 Million ↗
Yum China operates over 12,000 restaurants across 1,700 cities, serving quick-service and casual dining to mass-market consumers. 
Via The Motley Fool
News headline image
Nvidia Rival Cerebras Files for an IPO: What Investors Should Know ↗
Cerebras Systems is a fast-growing AI chipmaker whose customers include ChatGPT maker OpenAI, Amazon, and Meta Platforms. 
Via The Motley Fool
Topics Artificial Intelligence Initial Public Offering
News headline image
3 Bargain-Cheap Small Caps Worth a Second Look ↗
Via MarketBeat
News headline image
The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded... 
Via MarketMinute
Topics Economy World Trade
News headline image
Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer
BRUSSELS — In a major victory for one of the world’s leading pharmaceutical giants, the European Commission (EC) has officially granted marketing authorization for Merck & Co. (NYSE: MRK) blockbuster... 
Via MarketMinute
Topics Intellectual Property
News headline image
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the... 
Via Finterra
Topics Initial Public Offering
News headline image
AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results
AstraZeneca (NASDAQ: AZN) shares climbed 2.7% in early trading today, March 27, 2026, following the release of highly anticipated Phase 3 clinical trial results for its latest respiratory blockbuster... 
Via MarketMinute
Topics Intellectual Property
News headline image
The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery
The biotech sector has found its new North Star in 2026. As of mid-March, Moderna Inc. (NASDAQ: MRNA) has shocked Wall Street with a staggering 83% year-to-date gain, catapulting it to the upper... 
Via MarketMinute
Topics Artificial Intelligence Initial Public Offering Stocks
News headline image
This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment ↗
Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The $40 Billion Pivot: Kimberly-Clark and Kenvue Merger Redefines the Consumer Staples Landscape
In a move that signals a seismic shift in the global consumer goods sector, Kimberly-Clark (NYSE:KMB) is charging forward with its landmark $48.7 billion enterprise value acquisition of consumer health... 
Via MarketMinute
Topics Artificial Intelligence Lawsuit
News headline image
This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock ↗
Avantor delivers laboratory materials and specialized services to biopharma, healthcare, and advanced technology clients worldwide. 
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
News headline image
Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report ↗
Amgen Inc. (NASDAQ: AMGN) and GSK plc (NYSE: GSK) are reportedly set to announce their partnership with TrumpRx.gov. This collaboration is set to offer substantial discounts on prescription drugs. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
45 46 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.